Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Pharma Plans to Use M&A to Expand Overseas

publication date: Nov 16, 2017

Shanghai Pharma told Bloomberg that it wants to keep doing international deals to expand its portfolio of drug offerings. The company plans to acquire specialty drugs from foreign manufacturers, products that target cancer and cardiovascular disorders, along with branded generics from US or European (especially Switzerland or Germany) pharmas. It also hopes to acquire foreign manufacturing facilities and to sell its own products in large western markets. The news follows Shanghai Pharma's announcement yesterday that it will acquire Cardinal Health's China drug distribution business for $1.2 billion. More details....

Stock Symbols: (SHA: 600607) (NYSE: CAH)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.